Journals / Turkish Journal of Hematology / 2020 / Cilt: 37 - Sayı: 4

Comment: In Response to “CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML”

Pages
289–290
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

GAJENDRA, S. (2020). Comment: In Response to “CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML”. Turkish Journal of Hematology, Cilt: 37 - Sayı: 4, 289–290. https://ajindex.com/articles/412706

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Satlsar ES, Mosleh M, Mehrpouri M. CD9 is a very helpful marker for discriminating AML-M3 from HLA-DR negative non-M3 AML. Turk J Hematol 2020;37:287-289
  2. Dong HY, Kung JX, Bhardwaj V, McGill J. Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities. Am J Clin Pathol 2011;1:76-84
  3. Bain BJ, Béné MC. Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia. Acta Haematol 2019;141:232-244
  4. Zhou Y, Jorgensen JL, Wang SA, et al. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol. 2012;138:744-750
  5. Zhou Y, Jorgensen JL, Wang SA, Ravandi F, Cortes J, Kantarjian HM, Medeiros LJ, Konoplev S. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol 2012;138:744-750
  6. Kussick SJ, Stirewalt DL, Yi HS, Sheets KM, Pogosova-Agadjanyan E, Braswell S, Norwood TH, Radich JP, Wood BL. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia 2004;18:1591- 1598
  7. Syampurnawati M, Tatsumi E, Ardianto B, Takenokuchi M, Nakamachi Y, Kawano S, Kumagai S, Saigo K, Matsui T, Takahashi T, Nagai K, Nishio H, Yabe H, Kondo S, Hayashi Y. DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation. Leuk Res 2008;32:1141-1143
  8. Touzet L, Dumezy F, Roumier C, Berthon C, Bories C, Quesnel B, Preudhomme C, Boyer T. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Med 2019;8:1279-1288
  9. Liu YR, Zhu HH, Ruan GR, Qin Y-Z, Shi H-X, Lai Y-Y, Chang Y, Wang Y-Z, Lu D, Hao L, Li J-L, Li L-D, Jiang B, Huang X-J. NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes. Leuk Res 2013;37:737-741.